

# Belma Pojskic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10195782/publications.pdf>

Version: 2024-02-01

35  
papers

7,950  
citations

516710

16  
h-index

526287

27  
g-index

41  
all docs

41  
docs citations

41  
times ranked

10302  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
2	Familial chylomicronemia syndrome - Case report. Atherosclerosis, 2020, 315, e149-e150.	0.8	0
3	Lipid profile in young adults with acute myocardial infarction. Atherosclerosis, 2020, 315, e177.	0.8	0
4	Comparison of intubation condition and the quality of muscle relaxation between rocuronium and vecuronium using "timing principle". Medicinski Glasnik, 2020, 17, 7-14.	0.4	1
5	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
6	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	11.4	207
7	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
8	2 Statins Therapy In Acute Coronary Syndrome In Bosnia And Herzegovina. Atherosclerosis, 2019, 287, e193.	0.8	0
9	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753
10	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
11	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
12	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
13	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports, 2019, 21, 36.	4.8	13
14	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
15	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
16	Familial hypercholesterolemia in hospital screening program in Bosnia and Herzegovina. Atherosclerosis, 2018, 275, e178.	0.8	0
17	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
18	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163

#	ARTICLE	IF	CITATIONS
19	Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity. <i>Atherosclerosis</i> , 2018, 277, 278-281.	0.8	2
20	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	27.0	205
21	Influence of C-reactive protein on the occurrence and assessing of albuminuria severity in diabetics. <i>Medicinski Glasnik</i> , 2018, 15, 10-15.	0.4	2
22	Connection between foreign body in the eye and familial hypercholesterolemia â€œcase report. <i>Atherosclerosis</i> , 2017, 263, e228.	0.8	0
23	Risk factor for NAFLD and CHD â€œ similarity and differences. <i>Atherosclerosis</i> , 2017, 263, e259.	0.8	1
24	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	2.9	17
25	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
26	Stroke prevention in atrial fibrillation and â€œreal worldâ€™ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	3.3	40
27	The lipid fractions as risk factors for atherosclerosis in different age groups in Bosnian population. <i>Atherosclerosis</i> , 2016, 252, e109.	0.8	0
28	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
29	Influence of lipids on mortality and morbidity in people aged over 80 in Bosnia. <i>Atherosclerosis</i> , 2015, 241, e116.	0.8	0
30	Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer. <i>Medicinski Glasnik</i> , 2015, 12, 206-11.	0.4	1
31	Takayasu arteritis in bosnia- case report. <i>Atherosclerosis</i> , 2014, 235, e90.	0.8	0
32	Evaluation of Risk Markers Fluctuation During an Initial Therapy with Rosiglitazon in Patients Suffering from Metabolic Syndrome. <i>Bosnian Journal of Basic Medical Sciences</i> , 2009, 9, 320-328.	1.0	0
33	Acute Heart Failure After Myocardial Infarction. <i>Bosnian Journal of Basic Medical Sciences</i> , 2008, 7, 40-47.	1.0	3
34	Echocardiographic Monitoring of Patients with Heart Failure. <i>Bosnian Journal of Basic Medical Sciences</i> , 2008, 7, 339-344.	1.0	0
35	Cardiac Sarcoidosis Mimicking Takotsubo Syndrome. <i>Bosnian Journal of Basic Medical Sciences</i> , 2008, 8, 234-238.	1.0	2